Loeb & Loeb LLP is proud to sponsor the Maxim Group's Infectious Disease Virtual Conference taking place on May 5, 2020 where partner James N. Czaban will be speaking on the panel "A Tale of Two Agencies – The Emerging Dispute Over Market Incentives for Anti-Infective Product Development".
About the event:
The conference consists of four panels of companies in various stages of development, from early stage to near commercialization, that represent the next wave of innovation in the infectious disease sector. While COVID-19 has captured the world's attention for now, there is another pandemic that has been smoldering beneath the surface; drug resistant bacteria and fungi driving alarming rates of invasive disease, which result in high rates of mortality and a significant burden on the healthcare system. The lag in development of novel anti-infectives is multi-factorial, but moving through 2020 and beyond, there is a renaissance in drug development taking place that has not been observed for some time. This includes novel drugs and new drug classes, changes in regulatory guidelines and incentives for drug developers, changes to clinical trial design and execution, changes in views from payers and the investment community.
For more information, including how to register, please visit the event website.